For the quarter ending 2025-09-30, VRDN had $52,323K increase in cash & cash equivalents over the period. -$84,738K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Segment research and development expense | 81,105 | - |
| Segment general and administrative expense | 18,118 | - |
| Share-based compensation expense (see note 10) | 11,250 | - |
| License revenue-License | 70,000 | - |
| Other items | -5,874 | - |
| Net loss | -34,599 | -187,647 |
| Share-based compensation expense | 11,250 | 21,064 |
| Non-cash interest expense | 308 | - |
| Depreciation and amortization | 110 | 230 |
| Non-cash interest expense and amortization of debt issuance costs | - | 206 |
| Accretion and amortization of available-for-sale securities | 1,133 | 3,872 |
| Non-cash lease expense | -13 | -17 |
| Deferred revenue - related party | - | -144 |
| Net loss on disposal of equipment | 0 | - |
| Unbilled revenue | 70,000 | 0 |
| Prepaid expenses and other assets | -3,370 | -5,479 |
| Accounts payable | 1,546 | 6,396 |
| Accrued and other liabilities | 4,612 | -9,721 |
| Net cash used in operating activities | -84,611 | -168,026 |
| Purchases of short-term investments | 14,086 | 126,998 |
| Maturities of short-term investments | 140,290 | 302,906 |
| Purchase of property and equipment | 127 | 128 |
| Net cash provided by (used in) investing activities | 126,077 | 175,780 |
| Proceeds from the issuance of common stock-September2022ATMAgreement | - | 4,944 |
| Proceeds from sale of common stock in public offering | 0 | - |
| Proceeds from the issuance of common stock-January2024Public Offering | - | 0 |
| Proceeds from sale of common stock in at-the-market offerings | 14,904 | - |
| Payments of issuance costs associated with sale of common stock-Common Stock | 209 | 207 |
| Proceeds from the issuance of series b preferred stock, pursuant to september 2024 public offering | 0 | - |
| Payments of issuance costs associated with sale of common stock-Preferred Stock | 0 | - |
| Proceeds from issuance of common stock upon exercises of warrants | 0 | 1,618 |
| Proceeds from issuance of common stock upon exercises of stock options | 547 | 3,060 |
| Proceeds from issuance of common stock under employee stock purchase plan | 559 | 561 |
| Net cash provided by financing activities | 10,857 | 9,976 |
| Net increase in cash and cash equivalents | 52,323 | 17,730 |
| Cash and cash equivalents at beginning of period | 99,594 | - |
| Cash and cash equivalents at end of period | 169,647 | - |
Viridian Therapeutics, Inc. DE (VRDN)
Viridian Therapeutics, Inc. DE (VRDN)